Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Respiratory syncytial virus (RSV) is a common, highly contagious respiratory virus that primarily infects the nose, throat, lungs, and breathing passages. It is specific and pathogenic for humans and targets cells along the entire human respiratory tract—from the upper airways to the lungs. Infection leads to inflammation characterized by monocyte/T-cell infiltration, epithelial necrosis, submucosal edema, mucus overproduction, patchy tissue damage with airway obstruction due to sloughed epithelium and mucus plugs. Syncytia formation may occur—especially in immunocompromised patients—due to cell fusion mediated by F protein.
N/A
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Respiratory Syncytial Virus (RSV).